Robalzotan

Robalzotan

Systematic (IUPAC) name
(3R)-3-[di(cyclobutyl)amino]-8-fluoro-3,4-dihydro-2H-chromene-5-carboxamide
Clinical data
Legal status	Uncontrolled
Routes of administration	Oral
Identifiers
CAS Number	169758-66-1 Y
ATC code	none
PubChem	CID: 3055171
IUPHAR/BPS	72
ChemSpider	2316732
UNII	I18M56OGME Y
Chemical data
Formula	C18H23FN2O2
Molecular mass	318.174 g/mol
SMILES C1CC(C1)N(C2CCC2)[C@@H]3CC4=C(C=CC(=C4OC3)F)C(=O)N
InChI InChI=1S/C18H23FN2O2/c19-16-8-7-14(18(20)22)15-9-13(10-23-17(15)16)21(11-3-1-4-11)12-5-2-6-12/h7-8,11-13H,1-6,9-10H2,(H2,20,22)/t13-/m1/s1 Key:MQTUXRKNJYPMCG-CYBMUJFWSA-N
(verify)

Robalzotan (NAD-299, AZD-7371) is a selective antagonist at the 5-HT_1A receptor. It was shown to completely reverse the autoreceptor-mediated inhibition of serotonin release induced by the administration of selective serotonin reuptake inhibitors like citalopram in rodent studies. It was subsequently investigated by AstraZeneca as a potential antidepressant but like many other 5-HT_1A ligands was discontinued. Later on it was researched for other indications such as irritable bowel syndrome but was dropped once again.

See also

• Ebalzotan
• UH-301
• tianeptine